Navigation Links
NOVAVAX Awarded Nearly $1 Million in Grants from IRS Under Qualifying Therapeutic Discovery Project
Date:11/4/2010

ROCKVILLE, Md., Nov. 4, 2010 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that it has been awarded approximately $978,000 in grants under the Internal Revenue Service's Qualifying Therapeutic Discovery Project ("QTDP").  This program was created under the Patient Protection and Affordable Care Act of 2010 to provide tax credits or grants representing up to 50 percent of eligible qualified investments in therapeutic discovery projects during tax years 2009 and 2010.  

"We are gratified to receive this award in recognition of our efforts to develop novel vaccine candidates using our unique recombinant technology," said Dr. Rahul Singhvi, President and CEO of Novavax. "Novavax plans to use these funds to support advanced development of its novel virus-like-particle-based vaccine candidates, which include vaccines for seasonal and pandemic influenza, respiratory syncytial virus (RSV), and varicella-zoster virus (VZV)."  

About Novavax, Inc.

Novavax, Inc. is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology.  The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches.  Novavax is committed to using its VLP technology to create country-specific vaccine solutions.  The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India.  Additional information about Novavax is available on the company's website: www.novavax.com.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
3. Novavax CEO to Present at BIO Investor Forum 2008
4. Novavax CEO to Present at Oppenheimer 19th Annual Healthcare Conference
5. Novavax Announces Release Date of 2008 Third Quarter Financial Results and Investor Conference Call
6. Novavax CEO to Present at Lazard Capital Markets 5th Annual Healthcare Conference
7. Novavax CEO to Present at Piper Jaffray 20th Annual Healthcare Conference
8. Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
9. NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate
10. Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009
11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... July 1, 2015 R-Japan Co.,Ltd. obtained the license ... of Regenerative Medicine from the Ministry of Health, Labour and ... 2015. The fact that R- Japan ... the auditing from Pharmaceuticals and Medical Devices Agency (PMDA) on ... it to provide stem cell manufacturing service to medical institutions. ...
(Date:6/30/2015)... CALGARY , June 30, 2015 /PRNewswire/ - ... ("Shareholders") of common shares of Resverlogix have approved ... to Eastern Capital Limited of 5,600,000 units at ... Private Placement"), each unit being comprised of one ... for aggregate proceeds of approximately CAD$15 million; and ...
(Date:6/30/2015)... June 30, 2015  NASA astronaut Kjell Lindgren , ... on his first mission to the International Space Station ... to 9 a.m. EDT Tuesday, July 7. Lindgren ... City, Russia . The interviews will be ... highlighting his mission training. To schedule an interview, ...
(Date:6/30/2015)... , June 30, 2015  Today, Americord Registry, one ... announced Andrew Horne , a partner at Kirkland & ... Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   ... Americord,s Advisory Board," says Martin Smithmyer , CEO of ... his legal career that will assist Americord,s growth and vision." ...
Breaking Biology Technology:R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2Americord Registry Announces Andrew Horne as Advisory Board Member 2
... campaign season, and you've been poked and prodded by television ... John Kerry drank a beer at your neighborhood bar and ... Dick Cheney was spotted more in Wisconsin in 2004 than ... years. John Edwards has been in the state so often ...
... studies stem cells in his Primate Center lab. Photo ... Wis. James Thomson avoided talking ... the presidential election, explaining instead the science behind his ... on the University of Wisconsin-Madison campus since his 1998 ...
... Silicon Graphics Inc. Chippewa Valley, Wis. — ... in about 129 days, and it was the company's Chippewa ... the completion of the $50 million project for NASA ... space shuttle that crashed last year, runs on SGIs ...
Cached Biology Technology:Twenty ways you can tell this campaign has finally pushed you over the edge 2James Thomson plans to stay in Madison to study genesis of stem cells 2James Thomson plans to stay in Madison to study genesis of stem cells 3SGIs Wisconsin branch builds fastest supercomputer yet in four months 2
(Date:6/11/2015)... 2015 Daon, a global leader in ... IdentityX Mobile Authentication Platform v4.0 has been FIDO ... an industry consortium launched in 2013 to revolutionize ... authentication.  In order to receive certification, a company,s ... of tests that measure compliance and ensure interoperability ...
(Date:6/9/2015)... , June 09, 2015 Research ... addition of the "Gesture Recognition & Touchless ... (Consumer Electronics, Automotive, & Others), Product (Biometric & ... to 2020" report to their offering. ... market is expected to reach $ 23.55 Billion ...
(Date:6/5/2015)... Md. , June 5, 2015  Intrexon Corporation ... biology, today announced that it has determined the final ... all of its 17,830,305 shares of ZIOPHARM Oncology, Inc. ... about June 12, 2015, the distribution date, as a ... and on warrants to purchase shares of Intrexon common ...
Breaking Biology News(10 mins):Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 2Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 3Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 4
... 3, 2009 -- Despite the striking aromatic differences between ... nose,s neural circuitry suggests a haphazard patchwork where the ... not to be neighbors. Inexplicably, this seemingly random ... with cells that process the same scent located in ...
... the Swiss National Center of Competence in Research in ... to predict how breast cancer patients respond to chemotherapy, ... the future. In an article, ,A stroma-related gene signature ... published in Nature Medicine , Dr Pierre Farmer ...
... automobile, even during an economic downturn. Every day, hundreds ... remote places, to commute, and to reach the supermarket. ... trillions of dollars and millions of worker-hours. Miklos Szilagyi ... an apparent waste of resources, a serious producer of ...
Cached Biology News:Neural mapping paints a haphazard picture of odor receptors 2Stroma genomic signature predicts resistance to anthracyclin-based chemotherapy in breast cancer 2Stroma genomic signature predicts resistance to anthracyclin-based chemotherapy in breast cancer 3Defectors take the car, cooperators go by bus 2
... Lines ,High Quality, Functionally-Validated, Ion Channel Cell ... for having a critical role in nerve ... key function in pain, CNS and the ... been investigated in therapeutic areas, such as ...
Mouse polyclonal antibody raised against a partial recombinant CD320. NCBI Entrez Gene ID = 51293...
Mouse monoclonal antibody raised against a partial recombinant CHD8. NCBI Entrez Gene ID = CHD8...
Mouse monoclonal antibody raised against a partial recombinant DENR. NCBI Entrez Gene ID = DENR...
Biology Products: